Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,724,261
  • Shares Outstanding, K 237,998
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 167 M
  • EBITDA $ 176 M
  • 60-Month Beta 0.43
  • Price/Sales 11.22
  • Price/Cash Flow 37.15
  • Price/Book 11.12

Options Overview Details

View History
  • Implied Volatility 54.87% (-7.44%)
  • Historical Volatility 54.32%
  • IV Percentile 32%
  • IV Rank 23.51%
  • IV High 103.47% on 02/12/25
  • IV Low 39.93% on 08/22/25
  • Expected Move (DTE 13) 1.28 (6.47%)
  • Put/Call Vol Ratio 2.58
  • Today's Volume 1,552
  • Volume Avg (30-Day) 2,877
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 69,906
  • Open Int (30-Day) 116,252
  • Expected Range 18.57 to 21.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.19
  • Number of Estimates 1
  • High Estimate 0.19
  • Low Estimate 0.19
  • Prior Year 0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.76 +44.26%
on 11/07/25
20.22 -1.83%
on 12/04/25
+4.48 (+29.15%)
since 11/05/25
3-Month
13.76 +44.26%
on 11/07/25
20.22 -1.83%
on 12/04/25
+2.98 (+17.66%)
since 09/05/25
52-Week
13.50 +47.04%
on 03/04/25
25.67 -22.67%
on 04/28/25
+0.53 (+2.77%)
since 12/05/24

Most Recent Stories

More News
Adma Biologics: Q3 Earnings Snapshot

Adma Biologics: Q3 Earnings Snapshot

ADMA : 19.85 (-1.29%)
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase  3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase...

ADMA : 19.85 (-1.29%)
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 19.85 (-1.29%)
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14%...

IMCR : 38.78 (-3.57%)
CRMD : 10.56 (-0.75%)
ADMA : 19.85 (-1.29%)
Adma Biologics: Q2 Earnings Snapshot

Adma Biologics: Q2 Earnings Snapshot

ADMA : 19.85 (-1.29%)
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025...

ADMA : 19.85 (-1.29%)
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 19.85 (-1.29%)
Implied Volatility Surging for ADMA Biologics Stock Options

Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 16, 2026 $5.00 Call had some of the highest implied...

ADMA : 19.85 (-1.29%)
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions.ADMA Biologics markets plasma-derived...

GRFS : 8.85 (-0.45%)
ADMA : 19.85 (-1.29%)
Are Options Traders Betting on a Big Move in ADMA Biologics Stock?

Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2025 $10.00 Put had some of the highest implied...

ADMA : 19.85 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 20.56
2nd Resistance Point 20.33
1st Resistance Point 20.09
Last Price 19.85
1st Support Level 19.62
2nd Support Level 19.39
3rd Support Level 19.15

See More

52-Week High 25.67
Fibonacci 61.8% 21.02
Last Price 19.85
Fibonacci 50% 19.58
Fibonacci 38.2% 18.15
52-Week Low 13.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar